NEW YORK (GenomeWeb News) – Denator and two Dutch medical centers today announced a collaboration to develop a biomarker discovery platform for the diagnosis of cancer.
Denator, based in Gothenburg, Sweden, is working with Erasmus Medical Center and Amsterdam Medical Center to develop and verify a prototype platform for monitoring specific protein and peptide degradation patterns in biological fluids and tissue sections. Denator is applying its heat stabilization technology to the project, which is being funded by the EU Eurostars program.
Degradation patterns are specific for different tissue types and specific diseases, the partners said, and the platform being developed could result in the discovery of new disease biomarkers that in turn enable early diagnosis of cancer.
"To utilize specific degradation patterns correlating to specific cancer types could provide the research community with an important tool to help advance the understanding of the complexity of cancer and eventual early diagnosis," Theo Luider, head of the department of neurology at Erasmus Medical Center, said in a statement. "This project holds the potential of immensely facilitating the diagnostic process."